The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.
Opinion|Videos|April 27, 2026
Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum–pemetrexed (plat–pem) due to progression (PD): FLAURA2 exploratory analysis
Author(s)Helena A. Yu, MD
This presentation examines the effectiveness and clinical role of reusing chemotherapy after disease progression in patients with EGFR-mutated advanced non-small cell lung cancer.
Advertisement
This presentation explores the outcomes of reusing chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer after disease progression on initial treatment. It highlights patterns of treatment rechallenge, patient characteristics, and survival outcomes across different therapy approaches. The findings suggest that chemotherapy rechallenge remains a relevant option in subsequent treatment strategies.
Advertisement
Related to this article
A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.
Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5